THE HYMENOPTERA VENOM STUDY III--SAFETY OF VENOM IMMUNOTHERAPY

对蛇毒免疫疗法的安全性进行了上市后调查 出去。1,410例昆虫叮咬致敏感症患者 通过皮肤试验对FDA许可的膜翅目毒液敏感的有 已经免疫了。12%接种疫苗的患者出现不良反应 反应，类似于欧洲使用毒液产品的经验。多数 患者(92%)达到维持期，最常见的是在治疗8周后， 与批准的插入物中的剂量方案一致。最不利的 反应发生在积聚(1-50%g)和维护期间。不是 毒液反应史或皮肤对毒液的敏感度可以预测 患者在毒液过程中有过敏不良反应的风险 心理治疗。 这些数据证明了FDA许可的膜翅目昆虫的相对安全性。 根据包装插页使用时，毒液提取液。

A post marketing survey of the safety of venom immunotherapy was carried out. One thousand four hundred and ten insect sting alergic patients who were sensitive to FDA licensed hymenoptera venom by skin test were immunized. Twelve percent of patients immunized experienced adverse reactions, similar to the European experience with venom products. Most patients (92%) reached maintenance, most often 8 weeks into treatment, consistent with the dose regimen in the approved insert. Most adverse reactions occurred during buildup (1-50 %g) and at maintenance. No history of venom reactivity or skin sensitivity to venom predicted which patient was at risk of an allergic adverse reaction during venom therapy. These data demonstrate the relative safety of FDA licensed hymenoptera venom extracts when used according to package insert.